Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cudetaxestat DDI Study with Geneva Cocktail in Healthy Volunteers
NCT04814498Phase 1Completed
- Sponsor
- Blade Therapeutics, Inc.
- Start
- May 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cudetaxestat in idiopathic pulmonary fibrosis (IPF), sponsored by Blade Therapeutics, Inc. Primary endpoints: Area under the drug concentration-time curve from time zero to the last measurable concentration up to 16 days and Maximum observed drug concentration up to 16 days. Started May 2021; status: completed.
02
Drugs
cudetaxestat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04814498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814498.